US-based biotechnology company Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic ...

Kettering General Hospital (KGH) has set up a £250,000 state-of-the-art one-stop ophthalmology suite for patients who need ...

For those who struggle with insurance or can’t afford cutting-edge health care, there’s an eye-opening opportunity coming to ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Diabetes mellitus, more commonly known as diabetes, actually consists of many different types. Learn more about the ...

About AXPAXLI AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI) is an investigational, bioresorbable, hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase ...

Khanani, MD, MA, FASRS, Director of Clinic Research at Sierra Eye Associates, Reno, Nevada noted, "Real-world evidence shows that 40 to 50% of patients with wet AMD discontinue their injections due to ...

Type 2 diabetes is a condition where the body doesn’t make enough of the hormone insulin or use it effectively. Here, MDs ...

Therapeutics announced topline interim data from Part 1 of the SPECTRA clinical trial evaluating 4D-150 in diabetic macular ...

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level3E10 vg/eye demonstrated strong signals of clinical ...

Diabetes affects millions worldwide, and while most know about its impact on blood sugar and organ health, vision loss ...